The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis

The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis

Background: Bedaquiline (BDQ) has been designated as a Group A drug by the World Health Organization (WHO) for the management of multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). This systematic review and meta-analysis aim to evaluate the efficacy and...

Full description

Bibliographic Details
Main Authors:	Enyu Tong, Qian Wu, Yiming Chen, Zhengwei Liu, Mingwu Zhang, Yelei Zhu, Kunyang Wu, Junhang Pan, Jianmin Jiang
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Antibiotics
Subjects:	efficacy safety bedaquiline pulmonary tuberculosis systematic review meta-analysis
Online Access:	https://www.mdpi.com/2079-6382/12/9/1389

Similar Items

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021-03-01)

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis
by: Obaid Ur Rehman, et al.
Published: (2024-02-01)

Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
by: Shereen Katrak, et al.
Published: (2021-05-01)

Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
by: Yangming Ding, et al.
Published: (2023-10-01)

Mycobacterium tuberculosis – atpE gene profile of bedaquiline-treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia
by: Muhamad Frendy Setyawan, et al.
Published: (2023-01-01)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01)

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
by: Anna Starshinova, et al.
Published: (2022-11-01)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
by: Rong Li, et al.
Published: (2023-08-01)

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China
by: Tong E, et al.
Published: (2023-10-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study
by: Govind Desai, et al.
Published: (2022-05-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01)

Bedaquiline resistance in Mycobacterium tuberculosis during antimycobacterial therapy and its impact on clinical outcomes (clinical cases)
by: O. M. Raznatovska, et al.
Published: (2023-03-01)

The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data
by: Shanshan Li, et al.
Published: (2024-01-01)

The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline
by: Muhamad Frendy Setyawan, et al.
Published: (2023-10-01)

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
by: Camus Nimmo, et al.
Published: (2024-02-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)

Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review
by: Oki Nugraha Putra, et al.
Published: (2023-01-01)

Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
by: Gunar Günther, et al.
Published: (2024-03-01)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies
by: Mohammad A. M. Momin, et al.
Published: (2019-10-01)

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study
by: Ju Hwan Kim, et al.
Published: (2023-08-01)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
by: Sheng-Han Wu, et al.
Published: (2021-10-01)

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China
by: Guo Y, et al.
Published: (2023-12-01)

Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis
by: Prakasini Satapathy, et al.
Published: (2024-03-01)

Bedaquiline practice in treatment of extensively drug-resistant mycobacterium tuberculosis in children: Clinical cases
by: A. A. Akzhigitova, et al.
Published: (2022-05-01)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
by: Citra Cesilia, et al.
Published: (2023-01-01)

Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data
by: I Gusti Agung Ayu Putu Sri Darmayani, et al.
Published: (2022-07-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
by: Tae Sun Shim, et al.
Published: (2023-01-01)

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
by: Alena Skrahina, et al.
Published: (2016-01-01)

Extensively drug-resistant tuberculosis treated with bedaquiline: A case report in the particularly vulnerable tribal group of Madhya Pradesh, India
by: Prashant Mishra, et al.
Published: (2021-01-01)

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
by: Peter J. Choi, et al.
Published: (2020-03-01)